French focused ultrasound device maker, EDAP TMS SA, reports that the two-year follow-up phase has concluded for its multi-center U.S. Phase II/III clinical trial for the indication of low risk, localized prostate cancer. Data analysis is now underway, and the company is preparing a comprehensive Premarket Approval (PMA) submission, which is the next step in the FDA approval process.
EDAP Concludes Follow-up Phase of its U.S. Prostate Cancer Study
- Details
©
1999 - 2020
Focused Ultrasound Foundation